PermeaDerm Cuts Wound-Coverage Costs 70% vs Allograft in Pivotal Study
RCEL has more than doubled off its 52-week low of $3.22.
Summary
AVITA Medical's PermeaDerm-I randomized controlled trial met its primary endpoint, showing a 70% cost reduction versus cadaveric allograft ($148.70 vs $497.10 per %TBSA, p<0.001) with comparable clinical outcomes. The biosynthetic matrix also cut preparation time by 95.7% and achieved 94% graft take at one week, with no adverse events attributed to the product. This is the first public release of these data and strengthens the commercial case for PermeaDerm in acute wound care. The company will host a KOL webinar today at 4:30 p.m. ET to review the results. The news follows the August 6 Q2 report showing 18% revenue growth and raised guidance, and the August 11 amendment increasing PermeaDerm revenue share to 67–80%.
At the time of this announcement, RCEL was trading at $8.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $244.3M. The 52-week trading range was $3.22 to $8.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.